Healthcare Fraud Prevention and Regulatory Changes by Trump Administration
The Trump Administration and Congress have initiated measures to address inefficiencies and fraud within the healthcare sector. This move highlights an increase in enforcement and potential policy changes aimed at reducing federal spending on questionable practices. A coordinated task force focuses on improving fraud prevention and prosecution, with a temporary suspension of Medicare enrollment for specific Durable Medical Equipment suppliers due to historical issues within this sector.
One pivotal element of these federal initiatives is encouraging states and other entities to adopt similar enforcement measures. For example, the Centers for Medicare & Medicaid Services (CMS) withheld $259.5 million in Medicaid matching funds from Minnesota, citing insufficient program integrity. Despite approving Minnesota’s corrective action plan, CMS warned of further funding suspensions, leading to a lawsuit by Minnesota that was dismissed on procedural grounds.
On a broader scale, the House Committee on Energy and Commerce has reached out to state governors and Medicaid agencies for details on their program integrity efforts. CMS Administrator Dr. Mehmet Oz highlighted plans to expand fraud investigations, warning that non-compliance might lead to a loss of federal funding. This increased scrutiny has prompted states like Texas to enhance Medicaid fraud oversight, requiring Managed Care Organizations to maintain comprehensive investigative units.
In an effort to refine regulatory measures, CMS issued a Request for Information (RFI) under the Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH) initiative. This RFI seeks public input on modifying program integrity requirements, improving identity verification, and enhancing Medicare Advantage enrollment standards, among other areas.
The vigorous enforcement and policy reforms from CMS, Congress, and the Trump Administration underscore a shifting landscape in healthcare regulatory oversight. Industry participants, including providers and managed care organizations, are encouraged to evaluate compliance measures to mitigate potential impacts from heightened scrutiny and evolving regulatory expectations.